Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert ...
Autologous tumor-infiltrating lymphocytes (HS-IT101) with low-dose lymphodepletion and IL-2 infusion for the treatment of advanced solid tumors: A phase I clinical trial. This is an ASCO Meeting ...
A pilot study of lymphodepletion intensity for PBMC-derived, neoantigen-specific CD8+ T cells (Neo-Ts) therapy in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results